Researchers Initiate Evaluation of Potential Healthcare Cost Savings for Diachrome™ as a Medical Nutrition Therapy
Purchase, NY., June 9, 2004 – (Nutrition 21, Inc. Nasdaq: NXXI) – Interim results from an ongoing human clinical trial show that daily nutritional supplementation with a combination of chromium picolinate and biotin (marketed as Diachrome) significantly lowered blood sugar levels in patients with type 2 diabetes. The results, which evaluated 34 people over three months, were released Saturday in the Abstract Proceedings of the American Diabetes Association 64th Scientific Sessions in Orlando.
The randomized, double-blind, placebo-controlled study found that patients who added Diachrome to their prescription diabetes medication for three months significantly decreased their levels of glycosylated hemoglobin (HbA1c), a marker of long-term blood sugar control. Decreases in HbA1c were seen in 87% of patients taking Diachrome, while no significant change was seen in the placebo group.
“Given the chronic nature of type 2 diabetes and the devastating economic impact of managing type 2 diabetes, it is important to use the most cost-effective measure to help improve glycemic control in people inflicted with and at high risk for type 2 diabetes,” said David B. Nash, MD, MBA, Jefferson Medical College, Department of Health Policy, who has initiated an economic analysis of the use of Diachrome in patients with diabetes. “Chromium picolinate, when administered alone or in combination with biotin, as Diachrome, offers a low-cost intervention that decreases HbA1c levels which is beneficial to patients, third party payers and society as a whole.”
There are 18.2 million people in the United States who have diabetes.
Complications of type 2 diabetes include heart disease and stroke, blindness, nerve damage, kidney damage and foot complications resulting from poor blood flow.
Based upon previous study results, Dr. Nash found that diabetes patients could save between $405 and $729 annually in treatment costs by using Diachrome; those savings would double for patients with diabetes and heart disease, and triple for patients with diabetes, heart disease and hypertension. Dr. Nash reports that patients obtaining a 1.8 percentage point decrease in HbA1c could yield a $36,000 inflation adjusted lifetime cost savings per diabetic patient.
“Research supports Diachrome as a cost-effective adjuvant therapy for type 2 diabetes. The study is also evaluating the impact of Diachrome on overall disease management and healthcare cost,” said Gail Montgomery, president and CEO of Nutrition 21, which is collaborating with XLHealth Systems (formerly known as Diabetex) on this study. “The final clinical trial results and pharmaeconimc analysis should provide definitive evidence regarding the role of Diachrome supplementation in the management of type 2 diabetes.”
The study results are part of a larger multi-center ongoing clinical trial evaluating Diachrome’s effects on blood glucose levels, insulin resistance, and heart disease risk factors in people with type 2 diabetes. Enrollment in the study is expected to be completed this summer.
The ingredients in Diachrome are both Generally Recognized as Safe (GRAS) for use as in food and supplements.
About Nutrition 21
Nutrition 21 is a nutrition bioscience company, which develops and markets nutritional products, with health benefits substantiated by clinical research. The Company markets Chromax, the leading brand of chromium, and holds 35 patents for nutrition products, 22 for chromium compounds and their uses. For more information, consumers and health professionals, may visit www.nutrition21.com or www.diachrome.com or call 1-866-DIACHROME.
# # #